|
|
Vaccine Detail
|
HLA-A1, HLA-A2, and CD40-Ligand Pulsed Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: HLA-A1, HLA-A2, and CD40-Ligand Pulsed Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor (HLA-A1- and HLA-A2.1-restricted peptides) and influenza antigen peptides, and CD40-ligand (NCT00056134)
- Immunization Route: subcutaneous injection
- Description: The vaccine is made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which may be able to deliver cancer-killing substances directly to melanoma cells. Combining vaccine therapy with biological therapy may kill more tumor cells. (NCT00056134)
|
| Host Response |
|
|
| References |
NCT00056134: Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT00056134]
|
|
